Vaxart, Inc. filings document a clinical-stage biotechnology issuer focused on oral recombinant pill vaccines and a common stock quoted on the OTCQX Best Market under the symbol VXRT. The company’s regulatory record includes financial-result 8-K reports, registration statements and registration-rights disclosures tied to common stock financing, and exhibits covering material agreements.
The filings also cover board appointments and independence determinations, lease terminations and facility changes, capital structure items, revenue categories such as government contract and collaboration revenue, and formal market-status records, including a Form 25 for removal of the common stock from Nasdaq listing and registration.
Vaxart, Inc. Chief Medical Officer James F. Cummings reported an automatic share withholding tied to restricted stock units (RSUs). On February 2, 2026, 7,965 shares of common stock were withheld at $0.6085 per share to satisfy income tax obligations upon RSU vesting. After this transaction, he beneficially owned 737,792 common shares, which includes 75,618 shares acquired under Vaxart’s 2022 Employee Stock Purchase Plan. The transaction was reported as directly held ownership.
Vaxart, Inc. SVP and General Counsel Edward B. Berg reported a routine tax-related share withholding. On February 2, 2026, 9,265 shares of common stock were withheld at $0.6085 per share to cover income tax obligations from vested RSUs. After this transaction, Berg directly beneficially owned 684,858 common shares, which includes 70,781 shares acquired through Vaxart’s 2022 Employee Stock Purchase Plan.
Vaxart, Inc. senior vice president and chief scientific officer Sean Tucker reported a routine share withholding tied to restricted stock units (RSUs). On February 2, 2026, 9,265 shares of Vaxart common stock were withheld by the company at $0.6085 per share to cover income tax obligations upon RSU vesting.
After this tax-related withholding, Tucker beneficially owned 731,225 common shares directly. He also reported indirect holdings of 51,465 shares in joint tenancy with Frances Chang and Sean Tucker, and 9,060 shares held by his spouse.
Vaxart, Inc. disclosed that it has entered into a termination agreement with Britannia Pointe Grand Limited Partnership to end its headquarters lease at 170 Harbor Way, South San Francisco. The lease covers approximately 24,606 square feet and will now terminate effective May 15, 2026, instead of the original expiration date of March 31, 2029.
Vaxart will pay rent and reimbursable expenses through the termination date, but will not owe any termination fees or penalties. The change is part of the company’s ongoing efforts to identify cost reduction opportunities. Vaxart intends to relocate its headquarters and labs to one of its other offices in the South San Francisco area.
Vaxart, Inc. insider Michael Finney reported equity transactions in company stock. On December 4, 2025, he acquired 151,351 shares of common stock at a price of $0, reflecting the full vesting of previously granted restricted stock units. On the same date, 54,153 shares were disposed of at $0.37 per share, representing shares withheld by Vaxart to cover income tax obligations tied to the RSU vesting.
After these transactions, Finney beneficially owns 1,787,559 shares of Vaxart common stock directly, plus 100,000 shares held indirectly through the Lo Family Trust. The reported holdings also include 57,723 shares acquired under the Vaxart, Inc. 2022 Employee Stock Purchase Plan.
Vaxart insider Michael Finney has filed a notice to sell up to 40,000 shares of VXRT common stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC, with an approximate aggregate market value of $14,400.00 listed in the filing. The document also notes that 240,069,844 shares of the issuer’s stock are outstanding.
The 40,000 shares were originally acquired on 02/13/2018 in a private cash transaction from the issuer or an affiliate. In addition, the filing lists recent sales over the past three months, including 51,179 VXRT shares sold on 12/01/2025 for gross proceeds of $18,927.93. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about Vaxart.
Vaxart, Inc. director reports open-market stock purchases. A Vaxart (VXRT) director bought 15,000 shares of common stock on 11/17/2025 at a price of $0.41 per share and an additional 5,000 shares at $0.407 per share, both coded as open-market purchases. Following these transactions, the director beneficially owns 124,125 shares of Vaxart common stock in direct ownership form. The report notes that the filing was submitted late due to delays in receiving EDGAR access codes.
Vaxart, Inc. (VXRT) has had its common stock removed from listing and/or registration on the Nasdaq Stock Market LLC. Nasdaq filed Form 25 under Section 12(b) of the Securities Exchange Act of 1934, stating that it has complied with its rules to strike this class of securities from listing and withdraw its registration on the exchange. The filing specifies that the action concerns Vaxart’s common stock, which means the shares will no longer be listed for trading on Nasdaq.
Vaxart, Inc. (VXRT) reported an insider share purchase by a director. On 11/17/2025, the director bought 23,217 shares of common stock in an open-market transaction at $0.393 per share and a further 16,783 shares at $0.405 per share. After these purchases, the director beneficially owned 96,566 shares, held directly. The filing notes the person’s role as a director and confirms the report is filed by a single reporting person.
Vaxart, Inc. reported third‑quarter results highlighting a sharp rise in government contract revenue and a strengthened liquidity outlook. Revenue reached $72.4 million for the quarter, driven by HHS BARDA contracts tied to the ATI‑RRPV program, while operating expenses were $80.2 million, resulting in an operating loss of $7.8 million and a net loss of $8.1 million (basic and diluted loss per share of $0.04).
Cash, cash equivalents and short‑term investments totaled $28.8 million as of September 30, 2025. The balance sheet reflects $42.7 million in accounts receivable and $43.2 million in unbilled receivables from government contracts, alongside $64.8 million in deferred government revenue. Vaxart recognized $71.8 million of cost‑plus‑fixed‑fee revenue in Q3 under the 2024 ATI‑RRPV Contract.
After quarter‑end, Vaxart entered an exclusive license and collaboration with Dynavax, including a $25.0 million upfront fee and a $5.0 million equity purchase at $0.45 per share, providing approximately $30.0 million in total proceeds. Management reports these actions extend cash runway into the second quarter of 2027. Shares outstanding were 240,069,844 as of November 6, 2025.